Whitehawk Therapeutics has shifted its strategy to focus on three next-generation antibody-drug conjugates (ADCs) after selling its FYARRO asset and rebranding from Aadi Bioscience. The company’s rating was downgraded from 'Strong Buy' to 'Hold' due to the early-stage nature of its pipeline, competitive pressures, and unproven efficacy and safety of its modified ADCs. Key upcoming milestones include phase 1 data readouts for HWK-007 and HWK-016 expected in the first half of 2027, and an investigational new drug (IND) filing for HWK-206 planned for mid-2026. Despite a cash runway extending into the second half of 2028 following recent financing, significant clinical and competitive risks remain for investors to consider.
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
Ethereum is gaining strength, trading near $1,920 after surpassing its 26-day and 50-day EMAs, signaling renewed buying interest. The next key resistance is the 100-day EMA at around $1,944; a daily close above this could lead Ethereum toward the 200...
Bitcoin (BTC) is showing signs of recovery after a prolonged downtrend, breaking above its 26-day and 50-day exponential moving averages (EMAs) near $63,400 and $64,100 respectively. This technical rebound suggests strengthening short-term momentum a...
Fundstrat's Granny Shot US-Small & Mid-Cap ETF (GRNJ) has delivered strong year-to-date returns, beating similar ETFs like VOT and VOO despite its higher 0.75% expense ratio. The fund targets stocks at the intersection of major secular trends, partic...
ETHSystems, a new Ethereum-focused non-profit backed by Bitmine Immersion Technologies and Ethereum co-founder Joe Lubin, aims to enhance privacy on the Ethereum network for institutional use. This marks the third non-profit stepping in as the Ethere...
